LONA · Insider Trading
LeonaBio, Inc. Common Stock
Every open-market purchase and sale reported by LONA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | Joseph Edelman | Director | A | +84,000 deriv. | — |
| 2026-07-09 | Joseph Edelman | Director | A | +84,000 deriv. | — |
| 2026-06-24 | Peter B. Silverman | Director | A | +2,333 deriv. | — |
| 2026-06-24 | Fred Callori | Director | A | +2,333 deriv. | — |
| 2026-06-24 | Michael A. Panzara | Director | A | +28,000 deriv. | — |
| 2026-06-24 | Joseph Edelman | Director | A | +28,000 deriv. | — |
| 2026-06-24 | Barbara Kosacz | Director | A | +28,000 deriv. | — |
| 2026-06-24 | Natalie C. Holles | Director | A | +2,333 deriv. | — |
| 2026-06-24 | Grant Pickering | Director | A | +28,000 deriv. | — |
| 2026-06-24 | Kelly A Romano | Director | A | +28,000 deriv. | — |
| 2026-06-24 | James A Johnson | Director | A | +28,000 deriv. | — |
| 2026-05-07 | Natalie C. Holles | Director | A | +56,000 deriv. | — |
| 2026-05-07 | Peter B. Silverman | Director | A | +56,000 deriv. | — |
| 2026-05-07 | Fred Callori | Director | A | +56,000 deriv. | — |
| 2026-04-13 | Kevin Church | CHIEF SCIENTIFIC OFFICER | A | +300,000 deriv. | — |
| 2026-04-13 | Martin Javier San | CHIEF MEDICAL OFFICER | A | +350,000 deriv. | — |
| 2026-04-13 | Robert Renninger | CHIEF FINANCIAL OFFICER | A | +300,000 deriv. | — |
| 2026-04-13 | John M Fluke Jr | Director | A | +28,000 deriv. | — |
| 2026-04-13 | James A Johnson | Director | A | +28,000 deriv. | — |
| 2026-04-13 | Mark James Litton | PRESIDENT and CEO | A | +750,000 deriv. | — |
| 2026-04-13 | Joseph Edelman | Director | A | +28,000 deriv. | — |
| 2026-04-13 | Kelly A Romano | Director | A | +28,000 deriv. | — |
| 2026-04-13 | Grant Pickering | Director | A | +28,000 deriv. | — |
| 2026-04-13 | Barbara Kosacz | Director | A | +28,000 deriv. | — |
| 2026-04-13 | Mark Worthington | GENERAL COUNSEL and CCO | A | +300,000 deriv. | — |
| 2026-04-13 | Michael A. Panzara | Director | A | +28,000 deriv. | — |
| 2026-03-05 | Kevin Church | CHIEF SCIENTIFIC OFFICER | MIXED | +4,497 | −$7.30K |
| 2026-03-05 | Mark Worthington | GENERAL COUNSEL and CCO | MIXED | +4,398 | −$7.13K |
| 2026-03-05 | Robert Renninger | CHIEF FINANCIAL OFFICER | MIXED | +2,994 | −$4.87K |
| 2026-03-05 | Martin Javier San | CHIEF MEDICAL OFFICER | MIXED | +5,698 | −$9.24K |
| 2026-03-05 | Mark James Litton | PRESIDENT and CEO | MIXED | +17,098 | −$27.69K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Mark James Litton | PRESIDENT and CEO | 58,582 | $315.46K |
| Kevin Church | CHIEF SCIENTIFIC OFFICER | 25,178 | $135.58K |
| Mark Worthington | GENERAL COUNSEL and CCO | 19,704 | $106.11K |
| Martin Javier San | CHIEF MEDICAL OFFICER | 17,607 | $94.81K |
| Robert Renninger | CHIEF FINANCIAL OFFICER | 16,757 | $90.24K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LONA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.